Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lianhong Yang is active.

Publication


Featured researches published by Lianhong Yang.


Molecular Medicine Reports | 2014

Rifampicin improves neuronal apoptosis in LPS-stimulated co-cultured BV2 cells through inhibition of the TLR-4 pathway

Wei Bi; Lihong Zhu; Zhifen Zeng; Yanran Liang; Anding Xu; Jun Liu; Songhua Xiao; Lianhong Yang; Qiaoyun Shi; Li Guo; Enxiang Tao

Agents inhibiting microglial activation are attracting attention as candidate drugs for neuroprotection in neurodegenerative diseases. Recently, researchers have focused on the immunosuppression induced by rifampicin. Our previous study showed that rifampicin inhibits the production of lipopolysaccharide (LPS)-induced pro-inflammatory mediators and improves neuron survival in inflammation; however, the mechanism through which rifampicin inhibits microglial inflammation and its neuroprotective effects are not completely understood. In this study, we examined the effects of rifampicin on morphological changes induced by LPS in murine microglial BV2 cells. Then we investigated, in BV2 microglia, the effects of rifampicin on two signaling pathway componentss stimulated by LPS, the Toll-like receptor-4 (TLR-4) and the nuclear factor-κB (NF-κB). In addition, we co-cultured BV2 microglia and neurons to observe the indirect neuroprotective effects of rifampicin. Rifampicin inhibited LPS-stimulated expression of the TLR-4 gene. When neurons were co-cultured with LPS-stimulated BV2 microglia, pre-treatment with rifampicin increased neuronal viability and reduced the number of apoptotic cells. Taken together, these findings suggest that rifampicin, with its anti-inflammatory properties, may be a promising agent for the treatment of neurodegenerative diseases.


Neurological Research | 2012

Differentiation of HT22 neurons induces expression of NMDA receptor that mediates homocysteine cytotoxicity.

Zhongyan Zhao; Ruiyan Lu; Bei Zhang; Jun Shen; Lianhong Yang; Songhua Xiao; Jun Liu; William Z. Suo

Abstract Introduction: Neurotoxic homocysteine (Hcy) is thought to be an independent risk factor for neurodegenerative diseases, including Alzheimer’s disease. This study is to determine whether HT22 cells, a murine hippocampal neuronal model, can be used as an in vitro model, besides the primary neuronal cultures, to investigate the effects of Hcy. Materials and methods: MTS assay and Hoechst 33342/propidium iodide discrimination were used to assess the cell viability and cell death on undifferentiated and differentiated HT22 cells. Semi-quantitative reverse transcription polymerase chain reaction and western blot were used to determine the expression of N-methyl D-aspartate (NMDA) receptor. Results: We found that undifferentiated and differentiated HT22 cells responded to Hcy toxicity differentially, with the undifferentiated cells resistant while the differentiated cells sensitive. The underlying mechanism appeared to be the differential expression levels of NMDA glutamate receptor between the undifferentiated and differentiated cells. Similar to what have been observed in primary neuronal cultures, the Hcy toxicity in the differentiated HT22 cells was largely attenuated by NMDA receptor antagonists, MK-801 and memantine. Conclusion: These results suggest for the first time that the differentiation of HT22 cells could induce the expression of NMDA receptors, which lead to Hcy mediate concentration-dependent apoptosis-necrotic continuum of HT22 cell death. The differentiation status of the HT22 cells is important for modeling neurons in vitro, with the differentiated HT22 neurons resembling more characteristics of primary hippocampal neurons while the undifferentiated HT22 cells being proliferating neuronal precursor cells. The differentiated HT22 neurons can be used as a platform to study Hcy toxicity.


PLOS ONE | 2014

Rifampicin protects PC12 cells from rotenone-induced cytotoxicity by activating GRP78 via PERK-eIF2α-ATF4 pathway.

Qiaoyun Shi; Wei Kang Bi; Zhifen Zeng; Yanran Liang; Xia Wu; Songhua Xiao; Jun Liu; Lianhong Yang; Enxiang Tao

Rifampicin has been proposed as a therapeutic candidate for Parkinsons disease (PD). We previously showed that rifampicin was neuroprotective in PD models in vivo and in vitro. However, the molecular mechanisms underlying are not fully elucidated. In this study, using the comprehensive proteomic analysis, we identified that the 78 kDa glucose-regulated protein (GRP78), a hallmark of the unfolded protein response (UPR), was upregulated in rifampicin-treated PC12 cells. Western blot analysis confirmed GRP78 activation. GRP78 functions cytoprotectively in stressed cells, therefore, we hypothesized that GRP78 mediated rifampicin-induced neuroprotection. Using RNA interference, we found that GRP78 gene knockdown significantly attenuated the neuroprotective effects of rifampicin. Next, we examined three UPR transducers, namely, protein kinase RNA-like endoplasmic reticulum kinase (PERK), inositol requiring kinase α (IREα) and activating transcription factor 6 (ATF 6), and how they regulated rifampicin-stimulated GRP78 expression. Our results showed that PERK, eukaryotic initiation factor 2α (eIF2α), and activating transcription factor 4 (ATF4) were activated in rifampicin-treated PC12 cells. Silencing the ATF4 gene using RNAi inhibited GRP78 stimulation. Interestingly, we did not detect significant IREα activation, X-box binding protein 1 mRNA splicing, or ATF6 cleavage up to 24 h after rifampicin treatment. Taken together, our data suggested that rifampicin induced GRP78 via the PERK-eIF2α-ATF4 pathway to protect neurons against rotenone-induced cell damage. Targeting molecules in this pathway could be a novel therapeutic approach for PD treatment.


BMC Medical Education | 2014

Evaluating team-based, lecture-based, and hybrid learning methods for neurology clerkship in China: a method-comparison study.

Lianhong Yang; Long-Yuan Jiang; Bing Xu; Shu-Qiong Liu; Yanran Liang; Jin-Hao Ye; Enxiang Tao

BackgroundNeurology is complex, abstract, and difficult for students to learn. However, a good learning method for neurology clerkship training is required to help students quickly develop strong clinical thinking as well as problem-solving skills. Both the traditional lecture-based learning (LBL) and the relatively new team-based learning (TBL) methods have inherent strengths and weaknesses when applied to neurology clerkship education. However, the strengths of each method may complement the weaknesses of the other. Combining TBL with LBL may produce better learning outcomes than TBL or LBL alone. We propose a hybrid method (TBL + LBL) and designed an experiment to compare the learning outcomes with those of pure LBL and pure TBL.MethodsOne hundred twenty-seven fourth-year medical students attended a two-week neurology clerkship program organized by the Department of Neurology, Sun Yat-Sen Memorial Hospital. All of the students were from Grade 2007, Department of Clinical Medicine, Zhongshan School of Medicine, Sun Yat-Sen University. These students were assigned to one of three groups randomly: Group A (TBL + LBL, with 41 students), Group B (LBL, with 43 students), and Group C (TBL, with 43 students). The learning outcomes were evaluated by a questionnaire and two tests covering basic knowledge of neurology and clinical practice.ResultsThe practice test scores of Group A were similar to those of Group B, but significantly higher than those of Group C. The theoretical test scores and the total scores of Group A were significantly higher than those of Groups B and C. In addition, 100% of the students in Group A were satisfied with the combination of TBL + LBL.ConclusionsOur results support our proposal that the combination of TBL + LBL is acceptable to students and produces better learning outcomes than either method alone in neurology clerkships. In addition, the proposed hybrid method may also be suited for other medical clerkships that require students to absorb a large amount of abstract and complex course materials in a short period, such as pediatrics and internal medicine clerkships.


CNS Neuroscience & Therapeutics | 2012

Kallikrein Gene Transfer Induces Angiogenesis and Further Improves Regional Cerebral Blood Flow in the Early Period After Cerebral Ischemia/Reperfusion in Rats

Ruiyan Lu; Dan-Feng Luo; Songhua Xiao; Lianhong Yang; Jia Zhao; Er-Ni Ji; Enxiang Tao; Yigang Xing; Feng-Ying Zhu; Ping Luan; Jun Liu

SUMMARY  Aims: The aims of this study were to find out whether kallikrein could induce angiogenesis and affect the cerebral blood flow (rCBF) in the early period after cerebral ischemia/reperfusion (CI/R). Methods: The adenovirus carried human tissue kallikrein (HTK) gene was administrated into the periinfarction region after CI/R. At 12, 24, and 72 h after treatments, neurological deficits were evaluated; expression of HTK and vascular endothelial growth factor (VEGF) were detected by immunohistochemistry staining; the infarction volume was measured; and rCBF was examined by 14C‐iodoantipyrine microtracing technique. Results: The expression of VEGF was enhanced significantly in pAdCMV‐HTK group than controls over all time points (P < 0.05). Furthermore, the rCBF in pAdCMV‐HTK group increased markedly than controls at 24 and 72 h after treatment (P < 0.05), and the improved neurological deficit was accompanied by reduced infarction volume in pAdCMV‐HTK group 24 and 72 h posttreatment. Conclusion: In the early period after CI/R, kallikrein could induce the angiogenesis and improve rCBF in periinfarction region, and further reduce the infarction volume and improve the neurological deficits.


Neurotoxicology | 2017

Rifampicin inhibits rotenone-induced microglial inflammation via enhancement of autophagy

Yanran Liang; Tianen Zhou; Ying Chen; Danyu Lin; Sudan Peng; Dezhi Zheng; Zhifen Zeng; Ming Lei; Xia Wu; Kaixun Huang; Lianhong Yang; Songhua Xiao; Jun Liu; Enxiang Tao

HighlightsRifampicin pretreatment alleviated rotenone‐induced release of IL‐1&bgr; and IL‐6 in microglia.Rifampicin reversed rotenone‐induced mitochondrial membrane potential and ROS accumulation.Chloroquine abolishes the anti‐inflammatory and antioxidant effects of rifampicin.Rifampicin induced the expressions of autophagic markers and cytoplasmic vacuoles in microglia.Rifampicin promoted mitophagy in BV2 microglia exposed to rotenone. &NA; Mitochondrial and autophagic dysfunction, as well as neuroinflammation, are associated with the pathophysiology of Parkinsons disease (PD). Rotenone, an inhibitor of mitochondrial complex I, has been associated as an environmental neurotoxin related to PD. Our previous studies reported that rifampicin inhibited microglia activation and production of proinflammatory mediators induced by rotenone, but the precise mechanism has not been completely elucidated. BV2 cells were pretreated for 2 h with rifampicin followed by 0.1 &mgr;M rotenone, alone or in combination with chloroquine. Here, we demonstrate that rifampicin pretreatment alleviated rotenone induced release of IL‐1&bgr; and IL‐6, and its effects were suppressed when autophagy was inhibited by chloroquine. Moreover, preconditioning with 50 &mgr;M rifampicin significantly increased viability of SH‐SY5Y cells cocultured with rotenone‐treated BV2 cells in the transwell coculture system. Chloroquine partially abolished the neuroprotective effects of rifampicin pretreatment. Rifampicin pretreatment significantly reversed rotenone‐induced mitochondrial membrane potential reduction and reactive oxygen species accumulation. We suggest that the mechanism for rifampicin‐mediated anti‐inflammatory and antioxidant effects is the enhancement of autophagy. Indeed, the ratio of LC3‐II/LC3‐I in rifampicin‐pretreated BV2 cells was significantly higher than that in cells without pretreatment. Fluorescence and electron microscopy analyses indicate an increase of lysosomes colocalized with mitochondria in cells pretreated with rifampicin, which confirms that the damaged mitochondria were cleared through autophagy (mitophagy). Taken together, the data provide further evidence that rifampicin exerts neuroprotection against rotenone‐induced microglia inflammation, partially through the autophagy pathway. Modulation of autophagy by rifampicin is a novel therapeutic strategy for PD.


BioMed Research International | 2014

Inhibitory Effects of Edaravone in β-Amyloid-Induced Neurotoxicity in Rats

Feng He; Yan-Ping Cao; Feng-Yuan Che; Lianhong Yang; Songhua Xiao; Jun Liu

Amyloid protein can damage nerve cells through a variety of biological mechanisms including oxidative stress, alterations in calcium homeostasis, and proapoptosis. Edaravone, a potent free radical scavenger possessing antioxidant effects, has been proved neuroprotective effect in stroke patients. The current study aimed to investigate the effects of EDA in an Aβ-induced rat model of AD, by studying Aβ 1–40-induced voltage-gated calcium channel currents in hippocampal CA1 pyramidal neurons, learning and memory behavioral tests, the number of surviving cholinergic neurons in the basal forebrain, and the acetylcholine level in the hippocampus in this rat model of AD. The results showed that the Aβ 1–40-induced increase of I Ca can be inhibited by EDA in a dose-dependent manner. Treatment with EDA significantly improved Aβ 1–40-induced learning and memory performance. Choline acetyltransferase positive cells in basal forebrain and acetylcholine content in the hippocampus were increased by the administration of EDA as compared with the non-EDA treated Aβ 1–40 group. These results demonstrate that EDA can inhibit the neurotoxic effect of Aβ toxicity. Collectively, these findings suggest that EDA may serve as a potential complemental treatment strategy for AD.


PLOS ONE | 2012

Inhibition of 26S Protease Regulatory Subunit 7 (MSS1) Suppresses Neuroinflammation

Wei Kang Bi; Li-hong Zhu; Yanran Liang; Jun Liu; Lianhong Yang; Songhua Xiao; Anding Xu; Qiaoyun Shi; Enxiang Tao

Recently, researchers have focused on immunosuppression induced by rifampicin. Our previous investigation found that rifampicin was neuroprotective by inhibiting the production of pro-inflammatory mediators, thereby suppressing microglial activation. In this study, using 2-dimensional gel electrophoresis (2-DE) and mass spectrometry (MS), we discovered that 26S protease regulatory subunit 7 (MSS1) was decreased in rifampicin-treated microglia. Western blot analysis verified the downregulation of MSS1 expression by rifampicin. As it is indicated that the modulation of the ubiquitin-26S proteasome system (UPS) with proteasome inhibitors is efficacious for the treatment of neuro-inflammatory disorders, we next hypothesized that silencing MSS1 gene expression might inhibit microglial inflammation. Using RNA interference (RNAi), we showed significant reduction of IkBα degradation and NF-kB activation. The production of lipopolysaccharides-induced pro-inflammatory mediators such as inducible nitric oxide synthase (iNOS), nitric oxide, cyclooxygenase-2, and prostaglandin E2 were also reduced by MSS1 gene knockdown. Taken together, our findings suggested that rifampicin inhibited microglial inflammation by suppressing MSS1 protein production. Silencing MSS1 gene expression decreased neuroinflammation. We concluded that MSS1 inhibition, in addition to anti-inflammatory rifampicin, might represent a novel mechanism for the treatment of neuroinflammatory disorders.


CNS Neuroscience & Therapeutics | 2012

Basic Fibroblast Growth Factor Protects C17.2 Cells from Radiation-Induced Injury through ERK1/2

Ping Luan; Haihong Zhou; Bei Zhang; An-Ming Liu; Lianhong Yang; Xue-Ling Weng; Enxiang Tao; Jun Liu

To establish a radiation‐induced neural injury model using C17.2 neural stem cells (NSCs) and to investigate whether basic fibroblast growth factor (bFGF) can protect the radiation‐induced injury of C17.2 NSCs. Furthermore, we aim to identify the possible mechanisms involved in this model.


CNS Neuroscience & Therapeutics | 2014

Inhibitory Effect of Bcl-xL Gene on Toxicity Induced by Sodium Nitroprusside in SH-SY5Y cells

Lianhong Yang; Xiao-Dong Cai; Long-Yuan Jiang; Yanran Liang; Songhua Xiao; Shu-Qiong Liu; Enxiang Tao; Ping Luan; Jun Liu

Nitric oxide (NO) at physiological concentration is an intracellular messenger molecule in central nervous system (CNS). It plays a pivotal role in maintaining normal physiological function. While excessive NO produced by inducible NO synthase may lead to a variety of neurological diseases, such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and cerebral vascular disease, and so on [1,2]. It has been demonstrated that neural damage triggered by NO donor sodium nitroprusside

Collaboration


Dive into the Lianhong Yang's collaboration.

Top Co-Authors

Avatar

Jun Liu

Sun Yat-sen University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Enxiang Tao

Sun Yat-sen University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Zhifen Zeng

Sun Yat-sen University

View shared research outputs
Top Co-Authors

Avatar

Bei Zhang

Sun Yat-sen University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Xia Wu

Sun Yat-sen University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge